Abstract LB-A08: Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells

Liver cancer stem cells (LCSCs) are derived from damaged and transformed Hepatic progenitor cells (HPCs) during precancerous cirrhosis stage. Ras/Raf/MAPK and PI3K/Akt/mTOR signaling pathways are significantly deregulated during this process. The activation of PI3K/Akt/mTOR pathway in LCSC population is one of the reasons for acquired resistance to Sorafenib in advanced Hepatocellular carcinoma (HCC). Therefore, identifying novel inhibitors against LCSCs is highly essential. We elucidated the bioactivities of 10 different kinase inhibitors acting through PI3K/Akt/mTOR pathway on HCC cells and identified their potential for an inhibitory action on the LCSC population. We compared the LCSC inhibitory bioactivities of the inhibitors to that of DAPT (CSC inhibitor), DNA intercalators and Sorafenib. For this purpose, CD133+/EpCAM+ cells originated from HCC cells were analyzed by flow cytometry and effective inhibitors on LCSCs were further tested for their use in combination with Sorafenib. Treatment of cells with Sorafenib, and DNA intercalators resulted in enrichment of CD133+/EpCAM+ cells and sphere formation. Yet, Rapamycin, LY294002 and DAPT significantly reduced CD133/EpCAM positivity and dramatically decreased the number of LCSC spheres. Combination studies revealed that sequential treatment strategy decreased the ratio of LCSCs as opposed to Sorafenib treatment alone (Table). Additionally, a large panel of genes involved in cancer pathways were analyzed using Nanostring® nCounter® Technology to identify the differentially expressed genes in Rapamycin, Sorafenib, their combination or DAPT treated cells. Genes involved in stemness were down-regulated in cells treated with Rapamycin or DAPT, whereas JAG1 gene was found to be up-regulated in Sorafenib treated cells. Interleukin 8 (IL-8) was down-regulated upon treatment with DAPT, yet up-regulated upon Sorafenib treatment (Table). Following IL-8 inhibition with Reparixin, the ratio of CD133+/EpCAM+ cells and the LCSC sphere size and count decreased significantly, indicating that IL-8 signaling is crucial for the conservation of stemness features of liver cancer cells. In this study we demonstrated that PI3K/Akt/mTOR pathway inhibitors alter hepatic CSC composition and gene expression in favor or to the detriment of cancer stem cell survival. IL-8 signaling can be promising therapeutic target for LCSC.
AACR-NCI-EORTC International Conference,(October 26-30, 2017)


Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib
Kahraman, Deniz Cansen; Kahraman, Tamer; Atalay, Rengül (2018-07-01)
Liver cancer stem cells (LCSCs) are derived from damaged and transformed hepatic progenitor cells (HPCs) during precancerous cirrhosis stage. Ras/Raf/MAPK and PI3K/AKT/mTOR signaling pathways are significantly deregulated in liver cancer. The activation of PI3K/AKT/mTOR pathway in LCSC population is one of the reasons for acquired resistance to sorafenib in advanced hepatocellular carcinoma (HCC) patients. Therefore, identifying novel inhibitors targeting this pathway acting on LCSCs is highly essential. We...
Label-free enrichment of MCF7 breast cancer cells from leukocytes using continuous flow dielectrophoresis
Arslan, Zeynep Caglayan; Yalcin, Yagmur Demircan; Külah, Haluk (2022-04-01)
Circulating tumor cells (CTCs) present in the bloodstream are strongly linked to the invasive behavior of cancer; therefore, their detection holds great significance for monitoring disease progression. Currently available CTC isolation tools are often based on tumor-specific antigen or cell size approaches. However, these techniques are limited due to the lack of a unique and universal marker for CTCs, and the overlapping size between CTCs and regular blood cells. Dielectrophoresis (DEP), governed by the in...
Investigation of docetaxel and doxorubicin resistance in mcf-7 breast carcinoma cell line
Darcansoy İşeri, Özlem; Gündüz, Ufuk; Department of Biotechnology (2009)
Multidrug resistance phenotype of tumor cells describes resistance to wide range of structurally unrelated anticancer agents and is a serious limitation to effective chemotherapy. It is a multifactor yet not fully elucidated phenomenon by the involvement of diverse cellular pathways. Aim of this study was to investigate the resistance mechanisms developed against docetaxel and doxorubicin that are widely used in the treatment of breast cancer in model cell line MCF-7. Resistant sublines were developed by ap...
Differential gene expression analysis in drug resistant multiple myeloma cell lines
Mutlu, Pelin; Gündüz, Ufuk; Department of Biology (2009)
The emergence of drug-resistance of tumor cells is a major complication for succesful chemotherapy. In this study, the molecular mechanisms of resistance to prednisone, vincristine and melphalan in multiple myeloma cell lines, RPMI-8226 and U-266 were investigated. Drug resistance was induced by application of the drugs by stepwise dose increments and confirmed by XTT cytotoxicity assay. Gene expression analysis demostrated that MDR1 gene is one of the most important factor causing the multidrug resistance ...
Prolonged cytotoxic effect of colchicine released from biodegradable microspheres
Muvaffak, A; Gurhan, I; Hasırcı, Nesrin (2004-11-15)
One the main problems of cancer chemotherapy is the unwanted damage to normal cells caused by the high toxicities of anticancer drugs. Any system of controlled drug delivery that would reduce the total amount of drug required, and thus reduce the side effects, would potentially help to improve chemotherapy. In this respect, biodegradable gelatin microspheres were prepared by water/oil emulsion polymerization and by crosslinking with glutaraldehyde (GTA) as the drug-carrier system. Microspheres were loaded w...
Citation Formats
D. C. Kahraman and R. Atalay, “Abstract LB-A08: Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells,” presented at the AACR-NCI-EORTC International Conference,(October 26-30, 2017), Philadelphia, USA, 2017, Accessed: 00, 2021. [Online]. Available: https://hdl.handle.net/11511/72304.